S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:GTHX

G1 Therapeutics (GTHX) Stock Price, News & Analysis

$4.32
-0.15 (-3.36%)
(As of 03/28/2024 ET)
Today's Range
$4.30
$4.66
50-Day Range
$2.10
$4.83
52-Week Range
$1.08
$5.00
Volume
936,012 shs
Average Volume
910,916 shs
Market Capitalization
$225.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.33

G1 Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
116.0% Upside
$9.33 Price Target
Short Interest
Healthy
5.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.45
Upright™ Environmental Score
News Sentiment
1.06mentions of G1 Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$271,624 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.64) to ($0.26) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.22 out of 5 stars

Medical Sector

180th out of 938 stocks

Pharmaceutical Preparations Industry

70th out of 417 stocks

GTHX stock logo

About G1 Therapeutics Stock (NASDAQ:GTHX)

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor can protect bone marrow and reduce hematologic adverse events (AEs), as well as improve emerging treatments through myeloprotection which improve patients' overall anti-tumor immune responses combination with the antibody-drug conjugate; and treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

GTHX Stock Price History

GTHX Stock News Headlines

“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
GTHX Apr 2024 3.000 call
GTHX Apr 2024 3.500 put
GTHX Mar 2024 3.000 put
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Q4 2023 G1 Therapeutics Inc Earnings Call
G1 Therapeutics Inc (GTHX)
GTHX Jul 2024 2.500 put
Forecasting The Future: 5 Analyst Projections For G1 Therapeutics
GTHX Feb 2024 7.500 put
See More Headlines
Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/29/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GTHX
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.33
High Stock Price Target
$12.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+116.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-47,970,000.00
Pretax Margin
-54.36%

Debt

Sales & Book Value

Annual Sales
$82.51 million
Book Value
$0.68 per share

Miscellaneous

Free Float
47,903,000
Market Cap
$225.50 million
Optionable
Optionable
Beta
1.70
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. John E. Bailey Jr. (Age 59)
    CEO, President & Director
    Comp: $1.06M
  • Mr. Mark Avagliano (Age 48)
    Chief Business Officer
    Comp: $628.54k
  • Mr. John W. Umstead V (Age 39)
    Chief Financial Officer
  • Mr. Terry L. Murdock (Age 64)
    Chief Operating Officer
    Comp: $541.59k
  • Mr. William C. Roberts (Age 55)
    Vice President of Investor Relations & Corporate Communications
  • Ms. Monica R. Thomas
    General Counsel & Chief Compliance Officer
  • Mr. Evan Hicks M.B.A.
    Vice President of Marketing
  • Dr. Rajesh K. Malik Ch.B. (Age 65)
    M.B., M.D., Chief Medical Officer
    Comp: $596.37k
  • Mr. Andrew Perry (Age 51)
    Chief Commercial Officer
    Comp: $568.6k
  • Mr. Jeff Macdonald
    Senior Director of Investor Relations & Corporate Communications

GTHX Stock Analysis - Frequently Asked Questions

Should I buy or sell G1 Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GTHX shares.
View GTHX analyst ratings
or view top-rated stocks.

What is G1 Therapeutics' stock price target for 2024?

4 Wall Street analysts have issued twelve-month target prices for G1 Therapeutics' stock. Their GTHX share price targets range from $5.00 to $12.00. On average, they predict the company's stock price to reach $9.33 in the next year. This suggests a possible upside of 116.0% from the stock's current price.
View analysts price targets for GTHX
or view top-rated stocks among Wall Street analysts.

How have GTHX shares performed in 2024?

G1 Therapeutics' stock was trading at $3.05 at the start of the year. Since then, GTHX shares have increased by 41.6% and is now trading at $4.32.
View the best growth stocks for 2024 here
.

Are investors shorting G1 Therapeutics?

G1 Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 2,690,000 shares, a drop of 7.6% from the February 29th total of 2,910,000 shares. Based on an average daily volume of 1,440,000 shares, the short-interest ratio is presently 1.9 days.
View G1 Therapeutics' Short Interest
.

When is G1 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our GTHX earnings forecast
.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) released its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.06. The business had revenue of $14.87 million for the quarter, compared to analyst estimates of $12.83 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 106.04% and a negative net margin of 58.13%. During the same quarter in the previous year, the business posted ($0.73) EPS.

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

When did G1 Therapeutics IPO?

G1 Therapeutics (GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.82%), Vanguard Group Inc. (3.80%), Raymond James & Associates (1.09%), abrdn plc (0.82%), Needham Investment Management LLC (0.35%) and Level Four Advisory Services LLC (0.34%). Insiders that own company stock include Andrew Perry, James S Hanson, Jennifer K Moses, John E (Jack) Jr Bailey, John W V Umstead, Mark A Velleca, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock.
View institutional ownership trends
.

How do I buy shares of G1 Therapeutics?

Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GTHX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners